ABIM Advanced HF common mistakes
ABIM Advanced HF · Understand the traps and how to avoid them.
Reads LVEF off the echocardiogram report, sees 55%, and still starts sacubitril/valsartan plus a beta-blocker and spironolactone, quoting HFrEF mortality trials to justify it.
HFrEF trials are the most rehearsed evidence, so when a vignette contains dyspnea, congestion, and a low-ish EF, candidates reach for familiar neurohormonal drugs instead of re-classifying the phenotype and asking what is actually proven in that EF band.
What to do instead
Name the EF band first (reduced, mildly reduced, preserved), then state the evidence for that band before prescribing. For EF above 40%, build the plan around SGLT2 inhibition, diuretics for congestion, treatment of the cause, and comorbidity control, and say explicitly that the HFrEF neurohormonal mortality benefits are not established there.
Labels an older patient with hypertension and LVH as 'HFpEF', gives furosemide, and discharges without ordering a technetium pyrophosphate scan, serum free light chains, or iron studies.
Cardiac amyloidosis and iron deficiency produce the same dyspnea and edema as ordinary HFpEF, so the label becomes a substitute for finishing the differential. The exam deliberately hides red flags inside routine HFpEF vignettes.
What to do instead
For every new HFpEF diagnosis, answer three screening questions in the note: could this be ATTR amyloidosis (LVH over 12 mm, carpal tunnel release, biceps rupture, low-flow low-gradient aortic stenosis, ACE inhibitor intolerance); is there iron deficiency (ferritin under 100, or 100 to 299 with TSAT under 20); and is there a treatable cause such as valve disease, ischemia, or tachyarrhythmia.
Waits for systolic pressure below 90 mmHg before calling a patient shock, while the patient is cold and mottled with a narrow pulse pressure, lactate 3.6, and rising creatinine but a pressure of 104/78.
The textbook threshold is easy to memorize and the exam supplies normotensive shock precisely to test it. Candidates equate shock with hypotension rather than with hypoperfusion, so escalation is delayed until decompensation is irreversible.
What to do instead
Assess perfusion before pressure: mentation, skin temperature, capillary refill, urine output, lactate, creatinine trend, and mixed venous oxygen saturation. Diagnose cardiogenic shock when hypoperfusion is present regardless of the blood pressure number, then escalate immediately with inotrope or vasopressor support, invasive monitoring, and advanced HF consultation.
After LVAD implantation, treats falling MAP and a rising CVP with repeated crystalloid boluses, then cannot explain worsening hypoxia, oliguria, and falling pump flow.
Rapid fluid resuscitation is an ingrained ICU reflex, and the LVAD patient looks hypotensive. In reality the unloaded left ventricle cannot accept extra volume, so additional fluid distends the right ventricle, shifts the septum, worsens tricuspid regurgitation, and reduces LVAD filling.
What to do instead
For post-LVAD hypotension, examine the device and the echocardiogram before giving fluid: right ventricular function, septal position, aortic valve opening, and inflow cannula alignment. Treat right ventricular failure with inotropes such as milrinone or epinephrine, reduce pulmonary vascular resistance with inhaled nitric oxide or a PDE5 inhibitor, and reserve small fluid challenges for a genuinely under-filled ventricle.
Documents a low-flow alarm as 'likely dehydration', gives a fluid bolus, and never checks pump speed, power, pulsatility index, anticoagulation status, or the echocardiogram.
Device alarms present like generic vital sign abnormalities, and single-cause attribution is faster than a systematic review. Candidates also confuse the meaning of a low pulsatility index with hypovolemia alone rather than with under-filling of the pump from several possible causes.
What to do instead
Run a fixed checklist in order: pump parameters and trends (speed, power, pulsatility index, flow); volume status and suction events on echocardiography (inflow cannula position, septal shift); aortic insufficiency; and pump thrombosis with LDH, plasma free hemoglobin, and INR. Only after these are addressed should hypovolemia be concluded and treated.
Keeps an INTERMACS profile 3 patient on escalating dobutamine in the intensive care unit for days without ever activating transplant or durable MCS evaluation, or documenting why the patient is not a candidate.
Inotrope dependence feels like stable management, and each day's plan repeats the previous day's drip. Because no one asks the eligibility question out loud, the window for durable therapy closes after progressive multi-organ dysfunction and deconditioning.
What to do instead
On the day inotropes start, write the answers to three questions: is there a reversible cause; is this patient a candidate for heart transplant or durable mechanical support, and if so what workup is pending; and if not, is the goal now palliative care. Involve the advanced HF team early rather than after renal and hepatic failure develop.
Treats a high calculated PRA as an absolute contraindication to transplant, or accepts a negative virtual crossmatch without confirming that the unacceptable antigen list is complete and the antibody screen is current.
The calculated PRA is memorized as a severity score rather than as a probability of encountering an incompatible donor. Candidates conflate sensitization with inoperability, and they assume a virtual crossmatch is automatically accurate even when antibodies have not been re-profiled after a sensitizing event.
What to do instead
Interpret cPRA alongside the unacceptable antigen list and the actual prospective or retrospective crossmatch: a high cPRA predicts a longer wait and prompts broader organ sharing, desensitization, or both, not automatic exclusion. Verify that the antibody screen was repeated after transfusion, pregnancy, device implantation, or prior transplant before concluding that a donor is compatible.
Continues tacrolimus at the same dose after starting a triazole antifungal or another strong CYP3A4 inhibitor, and omits CMV and Pneumocystis prophylaxis in a CMV-seronegative recipient of a seropositive donor.
Immunosuppression gets memorized as a list of drug names rather than as pharmacology plus infection risk. The exam pairs transplant vignettes with interacting medications and serostatus mismatches precisely because candidates recall the drugs but not their consequences.
What to do instead
Before adding any drug, predict the interaction direction: azoles, verapamil, diltiazem, and grapefruit raise tacrolimus and cyclosporine, while rifampin lowers them; check trough levels within three to five days and adjust. Match prophylaxis to donor and recipient serostatus, treating CMV D positive to R negative as the highest-risk combination requiring prolonged prophylaxis or preemptive monitoring, and give Pneumocystis prophylaxis to all.
Averages the pulmonary artery wedge pressure from a wedged tracing without confirming position or reading at end-expiration, then assigns a PH group using mean pulmonary artery pressure alone with no pulmonary vascular resistance or fluid challenge.
Right heart catheterization numbers are treated as fixed data rather than as measurements that depend on technique and loading conditions. The post-capillary and combined pre- and post-capillary definitions are under-practiced, so mean pulmonary artery pressure alone becomes the label.
What to do instead
Confirm wedge position using waveform, oxygen saturation step-up, and fluoroscopy; read pressures at end-expiration in spontaneously breathing patients and average across several beats. Measure both wedge pressure and pulmonary vascular resistance, use a fluid challenge or provocative testing when the etiology is unclear, and diagnose combined post- and pre-capillary PH only when the wedge pressure is elevated and resistance exceeds 2 Wood units.
Starts a PAH-approved pulmonary vasodilator in a patient with group 2 or group 3 pulmonary hypertension and right ventricular dysfunction, then interprets the resulting hypotension and worsening edema as progression of heart failure.
Pulmonary vasodilators look like disease-specific therapy, and the memory link is strong between elevated pulmonary pressures and these drugs. Candidates forget that in left heart and lung disease they can precipitate pulmonary edema, and they forget that systemic vasodilation drops the aortic pressure that perfuses a failing right ventricle.
What to do instead
For group 2 and group 3 pulmonary hypertension, treat the underlying left heart or lung disease and avoid PAH-approved vasodilators outside specialist protocols. In right ventricular failure with hypotension, prioritize inotropes such as dobutamine or milrinone, add norepinephrine when needed to maintain right ventricular coronary perfusion, diurese cautiously, and reduce right ventricular afterload only when systemic pressure allows.